SCHEMBL587316

SCHEMBL587316

COC(=O)C1CCN(C(=O)OC)C(Cc2ccc(F)c(F)c2)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.47
▸ OPRK1 P41145 5/20 0.46
▸ HTT P42858 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ MMP1 P03956 1/20 0.38
▸ ADAM17 P78536 1/20 0.38
▸ SIGMAR1 Q99720 3/20 0.38
▸ DRD4 P21917 2/20 0.38
▸ TMEM97 Q5BJF2 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ DPP4 P27487 1/20 0.38
▸ DPP8 Q6V1X1 1/20 0.38
▸ DPP9 Q86TI2 1/20 0.38
▸ DPP7 Q9UHL4 1/20 0.38
▸ ATM Q13315 1/20 0.37
▸ DRD3 P35462 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL581092 0.91 ALDH1A1 (0.44) ALDH1A1OPRK1SIGMAR1DRD4TMEM97
SCHEMBL586719 0.89 OPRK1 (0.42) ALDH1A1OPRK1HTTSMN1; SMN2MAPT
SCHEMBL587185 0.89 OPRK1 (0.42) ALDH1A1OPRK1HTTSMN1; SMN2MAPT
SCHEMBL588023 0.87 OPRK1 (0.45) ALDH1A1OPRK1HTTSMN1; SMN2MAPT
SCHEMBL586767 0.86 ALDH1A1 (0.43) ALDH1A1OPRK1MAPTHPGDNPSR1
SCHEMBL587405 0.85 OPRK1 (0.43) ALDH1A1OPRK1HTTSMN1; SMN2MAPT
SCHEMBL586739 0.85 OPRK1 (0.50) ALDH1A1OPRK1HTTSMN1; SMN2MAPT
SCHEMBL3074901 0.85 ALDH1A1 (0.48) ALDH1A1OPRK1MAPTSIGMAR1DRD4
SCHEMBL582790 0.85 ALDH1A1 (0.48) ALDH1A1OPRK1MAPTSIGMAR1DRD4
SCHEMBL3076755 0.85 ALDH1A1 (0.48) ALDH1A1OPRK1MAPTSIGMAR1DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415378-B2 Isoxazol-3(2H)-one analogs as therapeutic agents ASTRAZENECA AB (SE) 2013-04-09 — — US disclosed
EP-2417131-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS AstraZeneca AB (SE) 2012-02-15 — — EP disclosed
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2010-10-14 — — US disclosed
WO-2010117323-A1 METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE ASTRAZENECA AB (SE) 2010-10-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS NR4A3, CBR3, OXER1 ALDH1A1 2598/4885OPRK1 164/4885HTT 2375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback